That window closed when the manufacturers caught up with demand and the FDA removed the drugs from the shortage list
To date, available clinical experience primarily derived from populations with T2DM or obesity receiving concomitant immunomodulatory therapies has not revealed major safety signals related to increased infection risk or immune suppression
A patient may be a candidate for GLP-1 injections if they are struggling with weight loss, appetite control, overeating, cravings, obesity, or weight-related health concerns
Table 1 Possible association between glucagon-like peptide 1 (GLP-1) and depression based on previous studies
Use of glucagon-like peptide-1 receptor agonists, known as GLP-1s, has skyrocketed among adults, but theyve only been approved for children in the last several years
Retatrutide is not FDA-approved, is not commercially available, and legitimate access is limited to appropriate clinical-trial participation